Evidence for Treatment of Aggressive Disease (RIGHT Choice): This Phase II study compared first-line ribociclib combined with endocrine therapy versus combination chemotherapy in premenopausal patients with aggressive HR+/HER2- advanced breast cancer, including those with investigator-assessed visceral crisis. The gene discussed is ERBB2; the disease is breast cancer.